There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AptarGroup (ATR – Research Report), Dexcom (DXCM – Research Report) and Aldeyra Therapeutics (ALDX – Research Report) with bullish sentiments.
AptarGroup (ATR)
In a report issued on April 25, Ghansham Panjabi from Robert W. Baird maintained a Buy rating on AptarGroup, with a price target of $150.00. The company’s shares closed last Monday at $146.38, close to its 52-week high of $148.51.
According to TipRanks.com, Panjabi is a 5-star analyst with an average return of
Currently, the analyst consensus on AptarGroup is a Strong Buy with an average price target of $162.33, a 12.0% upside from current levels. In a report released yesterday, William Blair also upgraded the stock to Buy.
See the top stocks recommended by analysts >>
Dexcom (DXCM)
In a report issued on April 25, Jeff Johnson from Robert W. Baird maintained a Buy rating on Dexcom, with a price target of $161.00. The company’s shares closed last Monday at $125.81.
According to TipRanks.com, Johnson is a 5-star analyst with an average return of
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $155.31, which is a 24.1% upside from current levels. In a report issued on April 10, UBS also maintained a Buy rating on the stock with a $163.00 price target.
Aldeyra Therapeutics (ALDX)
Leerink Partners analyst Marc Goodman maintained a Buy rating on Aldeyra Therapeutics on April 25. The company’s shares closed last Monday at $4.05.
According to TipRanks.com, Goodman is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aldeyra Therapeutics with a $9.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATR:
